Monte Rosa Therapeutics (GLUE) Common Equity (2023 - 2025)
Historic Common Equity for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $245.8 million.
- Monte Rosa Therapeutics' Common Equity rose 1965.37% to $245.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.8 million, marking a year-over-year increase of 1965.37%. This contributed to the annual value of $222.9 million for FY2024, which is 2437.15% up from last year.
- Latest data reveals that Monte Rosa Therapeutics reported Common Equity of $245.8 million as of Q3 2025, which was up 1965.37% from $268.1 million recorded in Q2 2025.
- Monte Rosa Therapeutics' Common Equity's 5-year high stood at $275.2 million during Q1 2025, with a 5-year trough of $152.5 million in Q1 2024.
- Over the past 3 years, Monte Rosa Therapeutics' median Common Equity value was $222.9 million (recorded in 2024), while the average stood at $219.6 million.
- In the last 5 years, Monte Rosa Therapeutics' Common Equity plummeted by 3742.19% in 2024 and then skyrocketed by 8041.03% in 2025.
- Over the past 3 years, Monte Rosa Therapeutics' Common Equity (Quarter) stood at $179.2 million in 2023, then rose by 24.37% to $222.9 million in 2024, then rose by 10.27% to $245.8 million in 2025.
- Its last three reported values are $245.8 million in Q3 2025, $268.1 million for Q2 2025, and $275.2 million during Q1 2025.